Elily Lilly acquires 3 vaccine firms in deals valued at nearly $3.8 billion, marking a major step in the company’s infectious disease strategy. The acquisitions include Curevo, LimmaTech Biologics, and Vaccine Company Inc., each bringing specialized vaccine technologies targeting shingles, bacterial infections, and Epstein-Barr Virus (EBV).
With the purchase of three vaccine-focused biotech companies, Eli Lilly continues to diversify beyond its blockbuster obesity and diabetes treatments. It strengthens the pharmaceutical giant’s vaccine and prevention pipeline as global concerns rise over antimicrobial resistance, viral diseases, and long-term health complications linked to infections.
The investors responded positively to this biotech deal, with Eli Lilly’s stock rising shortly after.
About the Three Vaccine Firms Acquired By Eli Lilly
As Elily Lilly acquires 3 vaccine firms, it highlights the company’s growing focus on preventative healthcare investments and vaccine innovation.
Curevo Acquisition by Lilly Focuses on Shingles Prevention
Lilly agreed to acquire Curevo for up to $1.5 billion. Curevo’s lead vaccine candidate, amezosvatein, is designed to prevent shingles in adults while improving tolerability compared to current vaccines.
In Phase 2 clinical studies, the amezosvatein vaccine reportedly matched immune response targets while reducing side effects such as fatigue, chills, and injection-site pain by more than half.
Daniel Skovronsky, chief scientific and product officer at Eli Lilly and Company, said the company wants to “prevent disease at its source rather than treat its consequences.”
The Curevo and Lilly deal may also position Lilly to compete with GSK’s shingles vaccine Shingrix, which currently dominates the market.
LimmaTech Biologics Deal With Lilly Targets Drug-Resistant Infections
The LimmaTech Biologics deal with Lilly is valued at up to $780 million. The Swiss biotech company LimmaTech develops vaccines targeting bacterial pathogens that are becoming increasingly difficult to treat because of antimicrobial resistance.
LimmaTech Biologics’ research includes vaccines for:
- Staphylococcus aureus
- Neisseria gonorrhoeae
- Chlamydia trachomatis
LimmaTech’s lead vaccine candidate, LTB-SA7, is currently in Phase 1 development and targets surgical-site infections caused by S. aureus.
The company’s broader research pipeline also focuses on infections linked to infertility and long-term complications that disproportionately affect women.
Vaccine Company Inc. Acquisition Expands EBV Vaccine Research
The Vaccine Company Inc. acquisition could cost Lilly up to $1.55 billion, including milestone-based payments.
Vaccine Company Inc. is developing In Vivo Nanoparticle (IVN) technology, which aims to create durable immune responses without the manufacturing challenges associated with traditional virus-like particle vaccines.
Its lead program targets Epstein-Barr Virus, a common virus increasingly linked to multiple sclerosis and several cancers. The EBV-focused platform was one of the most strategically important parts of Eli Lilly’s overall acquisition package.
Eli Lilly’s Expansion in Infectious Disease Signals Broader Strategy
As Elily Lilly acquires 3 vaccine firms, this announcement reflects a wider shift in the pharmaceutical industry toward vaccine development and infectious disease prevention.
While Lilly remains heavily associated with obesity drugs such as Zepbound and Mounjaro, the company has recently accelerated its portfolio by introducing new weight loss drugs Foundayo and retatrutide.
They are also expanding their pharmaceutical mergers and acquisitions strategy to diversify future revenue streams, including Kelonia Therapeutics for expansion in cancer.
Conclusion
Public health experts continue to warn that antimicrobial resistance could make some bacterial infections significantly harder to treat in the coming years. At the same time, researchers are uncovering stronger links between viral infections and chronic diseases, including dementia, stroke, infertility, and autoimmune conditions.
These findings are pushing pharmaceutical companies toward prevention-focused approaches rather than relying solely on treatment after illness develops.
Lilly stated that the acquisition of three vaccine-focused biotech companies reinforces its 150-year legacy in addressing major global health challenges while expanding research into vaccines capable of reducing the long-term burden of disease.
Even though Elily Lilly acquires 3 vaccine firms, it remains subject to customary regulatory approvals and closing conditions. Once finalized, the deals are expected to strengthen Lilly’s position in infectious disease research and next-generation vaccine development.
